1.Prediction model establishment for complete resolution of sentinel lymph node metastasis after neoadjuvant chemotherapy in breast cancer
Qing PAN ; Yicong NIU ; Cheng CHEN ; Dachang MA ; Jun WU
Journal of Clinical Surgery 2025;33(8):846-851
Objective To explore the factors associated with complete resolution of sentinel lymph node metastasis(pCR)after neoadjuvant chemotherapy in breast cancer and to establish a predictive model.Methods The medical records of 136 female patients with breast cancer who received neoadjuvant chemotherapy in the First Hospital of Lanzhou University from January 2022 to February 2024 were retrospectively analyzed.According to the 80/20 rule,the patients were randomly divided into a training set(108 cases)and a validation set(28 cases).Based on the pathological examination results of axillary lymph node dissection(ALND)after neoadjuvant chemotherapy in breast cancer patients,they were classified into the sentinel lymph node pCR group and non-pCR group.Multivariate logistic regression analysis was used to screen the independent risk factors of sentinel lymph nodes failing to reach pCR.Build a nomogram prediction model based on the screened risk factors.By drawing the receiver operating characteristic(ROC)curve calculation curve,the area under ROC curve,sensitivity and specificity are used to evaluate the discrimination of the model.Results Among the 108 breast cancer patients,46 cases achieved pCR in the sentinel lymph nodes,accounting for 42.59%(46 cases/108 cases).In addition,33 cases(30.56%)achieved pCR in the primary tumor lesion.The non-pCR group showed a higher proportion of stage Ⅲ clinical staging,lymph node short-axis reduction of less than 50%before and after treatment,tumor maximum diameter reduction of less than 50%before and after treatment,lymph node type Ⅲ classification,and blood flow grade Ⅲ compared to the pCR group(P<0.05).Multivariate logistic regression analysis showed that Clinical staging(OR=3.593,95%CI:1.276-10.121),lymph node short-axis reduction of less than 50%before and after treatment(OR=4.272,95%CI:1.517-12.032),tumor maximum diameter reduction of less than 50%before and after treatment(OR=3.710,95%CI:1.317-10.449),lymph node type(OR=3.827,95%CI:1.359-10.779),and blood flow grade(OR=4.764,95%CI:1.691-13.418)were identified as risk factors for not achieving pCR in the sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patients(P<0.05).The sensitivity of the risk model for predicting non-achievement of pCR in the sentinel lymph nodes after neoadjuvant chemotherapy in the training set of breast cancer patients was 0.826(95%CI:0.705-0.943),with a specificity of 0.826(95%CI:0.712-0.919)and an area under the ROC curve of 0.847(95%CI:0.738-0.952).In the validation set,the sensitivity for predicting non-achievement of pCR in the sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patients was 0.731(95%CI:0.608-0.904),with a specificity of 0.827(95%CI:0.713-0.941)and an area under the ROC curve of 0.834(95%CI:0.729-0.951).Conclusion Clinical staging,changes in lymph node short-axis before and after treatment,changes in tumor maximum diameter before and after treatment,lymph node type,and blood flow grade are associated with pCR in the sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patients.Constructing a predictive model can help evaluate the pCR status of sentinel lymph nodes after neoadjuvant chemotherapy.
2.Discussion on the effects of Qizhi Tongluo Prescription on renal damage in rats with membranous nephropathy based on the Shh/Gli1 signaling pathway
Yicong ZHAO ; Yuhan NIU ; Yuan LI ; Xiaowei JU ; Qian LIU ; Guodong YUAN ; Qian ZHANG ; Suzhi CHEN ; Chuchu CHEN ; Jinchuan TAN ; Fengwen YANG
International Journal of Traditional Chinese Medicine 2025;47(8):1095-1102
Objective:To observe the effects of Qizhi Tongluo Prescription on renal interstitial fibrosis in rats with membranous nephropathy based on the Shh/Gli1 signaling pathway; To explore its intervention mechanism.Methods:Totally 60 male SD rats were divided into blank group ( n=10) and model group ( n=50) using random number table method. The model of membranous nephropathy was established according to the modified Border method. The successfully modeling rats were divided into model group, benazepril group and Qizhi Tongluo Prescription low-, medium- and high-dosage groups using random number table method. Benazepril group was gavaged with benazepril hydrochloride 10 mg/kg, Qizhi Tongluo Prescription low-, medium- and high-dosage groups were gavaged with Qizhi Tongluo Prescription solution 1.22 g/kg, 2.43 g/kg and 4.86 g/kg, and blank group and model group were gavaged with equal volume of normal saline, once a day, for 4 weeks. The 24-hour urine was collected to detect the 24-hour urinary protein quantification, and the blood was taken from the abdominal aorta to detect the levels of total cholesterol (TC), triglyceride(TG), and serum albumin(ALB); the pathological changes of rat kidney were observed by light microscope and transmission electron microscope; the protein expressions of sonic hedgehog factor (Shh), zinc finger protein 1 (Gli1) and α-smooth muscle actin (SMA) in renal tissues were detected by immunohistochemistry; the protein expressions of Shh, Gli1, α-SMA, TGF-β1, Collagen Ⅳ and plasminogen activator inhibitor-1 (PAl-1) in renal tissues were detected by Western blot. Results:Compared with the model group, the quantitative level of 24-hour urinary protein of rats in each administration group decreased ( P<0.05), serum TC and TG levels increased ( P<0.05), ALB level decreased ( P<0.05), the positive expressions of Shh, Gli1, α-SMA protein in renal tissue decreased ( P<0.05), and the protein expressions of Shh, Gli1, α-SMA, Collagen Ⅳ, TGF-β1, PAI-1 in renal tissue decreased ( P<0.05). Conclusion:Qizhi Tongluo Prescription can improve renal interstitial fibrosis in membranous nephropathy rats, possibly by inhibiting the Shh/Gli1 signaling pathway to delay renal interstitial fibrosis.
3.Prediction model establishment for complete resolution of sentinel lymph node metastasis after neoadjuvant chemotherapy in breast cancer
Qing PAN ; Yicong NIU ; Cheng CHEN ; Dachang MA ; Jun WU
Journal of Clinical Surgery 2025;33(8):846-851
Objective To explore the factors associated with complete resolution of sentinel lymph node metastasis(pCR)after neoadjuvant chemotherapy in breast cancer and to establish a predictive model.Methods The medical records of 136 female patients with breast cancer who received neoadjuvant chemotherapy in the First Hospital of Lanzhou University from January 2022 to February 2024 were retrospectively analyzed.According to the 80/20 rule,the patients were randomly divided into a training set(108 cases)and a validation set(28 cases).Based on the pathological examination results of axillary lymph node dissection(ALND)after neoadjuvant chemotherapy in breast cancer patients,they were classified into the sentinel lymph node pCR group and non-pCR group.Multivariate logistic regression analysis was used to screen the independent risk factors of sentinel lymph nodes failing to reach pCR.Build a nomogram prediction model based on the screened risk factors.By drawing the receiver operating characteristic(ROC)curve calculation curve,the area under ROC curve,sensitivity and specificity are used to evaluate the discrimination of the model.Results Among the 108 breast cancer patients,46 cases achieved pCR in the sentinel lymph nodes,accounting for 42.59%(46 cases/108 cases).In addition,33 cases(30.56%)achieved pCR in the primary tumor lesion.The non-pCR group showed a higher proportion of stage Ⅲ clinical staging,lymph node short-axis reduction of less than 50%before and after treatment,tumor maximum diameter reduction of less than 50%before and after treatment,lymph node type Ⅲ classification,and blood flow grade Ⅲ compared to the pCR group(P<0.05).Multivariate logistic regression analysis showed that Clinical staging(OR=3.593,95%CI:1.276-10.121),lymph node short-axis reduction of less than 50%before and after treatment(OR=4.272,95%CI:1.517-12.032),tumor maximum diameter reduction of less than 50%before and after treatment(OR=3.710,95%CI:1.317-10.449),lymph node type(OR=3.827,95%CI:1.359-10.779),and blood flow grade(OR=4.764,95%CI:1.691-13.418)were identified as risk factors for not achieving pCR in the sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patients(P<0.05).The sensitivity of the risk model for predicting non-achievement of pCR in the sentinel lymph nodes after neoadjuvant chemotherapy in the training set of breast cancer patients was 0.826(95%CI:0.705-0.943),with a specificity of 0.826(95%CI:0.712-0.919)and an area under the ROC curve of 0.847(95%CI:0.738-0.952).In the validation set,the sensitivity for predicting non-achievement of pCR in the sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patients was 0.731(95%CI:0.608-0.904),with a specificity of 0.827(95%CI:0.713-0.941)and an area under the ROC curve of 0.834(95%CI:0.729-0.951).Conclusion Clinical staging,changes in lymph node short-axis before and after treatment,changes in tumor maximum diameter before and after treatment,lymph node type,and blood flow grade are associated with pCR in the sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patients.Constructing a predictive model can help evaluate the pCR status of sentinel lymph nodes after neoadjuvant chemotherapy.

Result Analysis
Print
Save
E-mail